Trial Profile
Effect of Administration of Licensed TIV Vaccine on the Safety and Immunogenicity of an Unadjuvanted Sanofi Pasteur H1N1 Influenza Vaccine in Healthy Adult and Elderly Populations.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 31 Jul 2012 Actual end date changed from May 2010 to Apr 2010 as reported by ClinicalTrials.gov.
- 27 Jan 2012 Actual end date changed from Apr 2010 to May 2010 as reported by ClinicalTrials.gov.
- 04 Nov 2011 Additional trial identifier N01AI80003C identified as reported by ClinicalTrials.gov.